Reports Q3 revenue $10.91M vs $5.103M last year. “The past few months at MeiraGTx (MGTX) have been highlighted by exceptional clinical, regulatory, and research and development advancements,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “In October, we announced positive data from our AAV-GAD bridging study using material manufactured in house at MeiraGTx. This study was a randomized, sham-controlled clinical study of AAV-GAD for the treatment of Parkinson’s disease, demonstrating that the treatment is safe and leads to significant and clinically meaningful improvements in key efficacy endpoints including UPDRS Part 3 ‘off’ score and PDQ-39 quality of life measure. Based on these extremely promising results, we are engaging with global regulatory agencies to initiate a Phase 3 registrational study.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: